Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers.
French JD., Ghoussaini M., Edwards SL., Meyer KB., Michailidou K., Ahmed S., Khan S., Maranian MJ., O'Reilly M., Hillman KM., Betts JA., Carroll T., Bailey PJ., Dicks E., Beesley J., Tyrer J., Maia A-T., Beck A., Knoblauch NW., Chen C., Kraft P., Barnes D., González-Neira A., Alonso MR., Herrero D., Tessier DC., Vincent D., Bacot F., Luccarini C., Baynes C., Conroy D., Dennis J., Bolla MK., Wang Q., Hopper JL., Southey MC., Schmidt MK., Broeks A., Verhoef S., Cornelissen S., Muir K., Lophatananon A., Stewart-Brown S., Siriwanarangsan P., Fasching PA., Loehberg CR., Ekici AB., Beckmann MW., Peto J., dos Santos Silva I., Johnson N., Aitken Z., Sawyer EJ., Tomlinson I., Kerin MJ., Miller N., Marme F., Schneeweiss A., Sohn C., Burwinkel B., Guénel P., Truong T., Laurent-Puig P., Menegaux F., Bojesen SE., Nordestgaard BG., Nielsen SF., Flyger H., Milne RL., Zamora MP., Arias Perez JI., Benitez J., Anton-Culver H., Brenner H., Müller H., Arndt V., Stegmaier C., Meindl A., Lichtner P., Schmutzler RK., Engel C., Brauch H., Hamann U., Justenhoven C., GENICA Network None., Aaltonen K., Heikkilä P., Aittomäki K., Blomqvist C., Matsuo K., Ito H., Iwata H., Sueta A., Bogdanova NV., Antonenkova NN., Dörk T., Lindblom A., Margolin S., Mannermaa A., Kataja V., Kosma V-M., Hartikainen JM., kConFab Investigators None., Wu AH., Tseng C-C., Van Den Berg D., Stram DO., Lambrechts D., Peeters S., Smeets A., Floris G., Chang-Claude J., Rudolph A., Nickels S., Flesch-Janys D., Radice P., Peterlongo P., Bonanni B., Sardella D., Couch FJ., Wang X., Pankratz VS., Lee A., Giles GG., Severi G., Baglietto L., Haiman CA., Henderson BE., Schumacher F., Le Marchand L., Simard J., Goldberg MS., Labrèche F., Dumont M., Teo SH., Yip CH., Ng C-H., Vithana EN., Kristensen V., Zheng W., Deming-Halverson S., Shrubsole M., Long J., Winqvist R., Pylkäs K., Jukkola-Vuorinen A., Grip M., Andrulis IL., Knight JA., Glendon G., Mulligan AM., Devilee P., Seynaeve C., García-Closas M., Figueroa J., Chanock SJ., Lissowska J., Czene K., Klevebring D., Schoof N., Hooning MJ., Martens JWM., Collée JM., Tilanus-Linthorst M., Hall P., Li J., Liu J., Humphreys K., Shu X-O., Lu W., Gao Y-T., Cai H., Cox A., Balasubramanian SP., Blot W., Signorello LB., Cai Q., Pharoah PDP., Healey CS., Shah M., Pooley KA., Kang D., Yoo K-Y., Noh D-Y., Hartman M., Miao H., Sng J-H., Sim X., Jakubowska A., Lubinski J., Jaworska-Bieniek K., Durda K., Sangrajrang S., Gaborieau V., McKay J., Toland AE., Ambrosone CB., Yannoukakos D., Godwin AK., Shen C-Y., Hsiung C-N., Wu P-E., Chen S-T., Swerdlow A., Ashworth A., Orr N., Schoemaker MJ., Ponder BAJ., Nevanlinna H., Brown MA., Chenevix-Trench G., Easton DF., Dunning AM.
Analysis of 4,405 variants in 89,050 European subjects from 41 case-control studies identified three independent association signals for estrogen-receptor-positive tumors at 11q13. The strongest signal maps to a transcriptional enhancer element in which the G allele of the best candidate causative variant rs554219 increases risk of breast cancer, reduces both binding of ELK4 transcription factor and luciferase activity in reporter assays, and may be associated with low cyclin D1 protein levels in tumors. Another candidate variant, rs78540526, lies in the same enhancer element. Risk association signal 2, rs75915166, creates a GATA3 binding site within a silencer element. Chromatin conformation studies demonstrate that these enhancer and silencer elements interact with each other and with their likely target gene, CCND1.